Value of thyroid transcription factor (TTF)-1 for diagnosis and prognosis of patients with locally advanced or metastatic small cell lung cancer
The aim of this study was to analyze the frequency of Thyroid Transcription Factor (TTF)-1 expression in small cell lung cancer (SCLC) and its value for the diagnosis of SCLC, the response to first line treatment as well as the prognostic impact on overall survival (OS). We analyzed a total of 294 p...
Gespeichert in:
| Veröffentlicht in: | Diagnostic pathology 2015-04, Vol.10 (1), p.21-21, Article 21 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 21 |
|---|---|
| container_issue | 1 |
| container_start_page | 21 |
| container_title | Diagnostic pathology |
| container_volume | 10 |
| creator | Misch, Daniel Blum, Torsten Boch, Christian Weiss, Timo Crolow, Catharina Griff, Sergej Mairinger, Thomas Bauer, Torsten T Kollmeier, Jens |
| description | The aim of this study was to analyze the frequency of Thyroid Transcription Factor (TTF)-1 expression in small cell lung cancer (SCLC) and its value for the diagnosis of SCLC, the response to first line treatment as well as the prognostic impact on overall survival (OS).
We analyzed a total of 294 patients (m, n = 184; f, n = 110) with SCLC (stage IIIA, n = 32; IIIB, n = 87; IV, n = 175) diagnosed in our institution between January 2005 and December 2008. Patient's characteristics comprising age, gender, histology and first line treatment were included into the analyses. For the follow-up of patients the governmental death registrar was used. The TTF-1 immunostaining was prospectively performed. CT scans of all patients were reviewed and response to treatment was evaluated using the Response Evaluation Criteria In Solid Tumors 1.0 (RECIST) criteria.
A total of 221 of the 294 patients were eligible for analysis. Patients with TTF-1-positive SCLC had a median OS of 374 (95% CI 306-442) days. The OS of patients with TTF1-negative SCLC was 290 (95% CI 191-389) days, which was not significantly shorter (p = 0.254). Also stratification for tumor stage did not reveal significant difference in OS. Analyzing the disease control rate (DCR) in patients with metastatic disease (stage IV), we observed a significantly (p = 0.006) improved response to treatment in the group of patients with TTF-1-expression (DCR 86% vs. 56%). Regarding the overall response rates (ORR) in the entire population, there was no difference observed between both subgroups. (TTF-1-pos. 75.3% vs. TTF-1-neg. 71.4%; p = 0.642).
The diagnostic information of TTF-1 in SCLC seems to be limited. TTF-1 had no prognostic value concerning OS, but may serve as a predictor for response to first line chemotherapy.
The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/5811254651472285. |
| doi_str_mv | 10.1186/s13000-015-0250-z |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4391673</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A541546342</galeid><sourcerecordid>A541546342</sourcerecordid><originalsourceid>FETCH-LOGICAL-c466t-2af1f24254fe4d711a1122d91d690a935d3cd5a20c8f5e82aff942e1464ad0f93</originalsourceid><addsrcrecordid>eNptks9qFTEUxoMotlYfwI0E3NTF1CSTZGY2QilWhYKbq9twzJ97IzPJmGQqt0_hI5vhXksLEkhOkt_3cQ58CL2m5ILSXr7PtCWENISKhjBBmrsn6JR2XDZUDPLpg_oEvcj5JyFcCEaeoxMm-n7oO3KK_nyHcbE4Olx2-xS9wSVByDr5ufgYsANdYsLnm831u4ZiV2vjYRti9hlDMHhO8XirHjMUb0PJ-LcvOzxGDeO4x2BuIWhrcBVPtkAuFdM4T_UXa1u3cQlbrFcovUTPHIzZvjqeZ-jb9cfN1efm5uunL1eXN43mUpaGgaOOcSa4s9x0lAKljJmBGjkQGFphWm0EMKJ7J2xfcTdwZimXHAxxQ3uGPhx85-XHZI2ubScY1Zz8BGmvInj1-Cf4ndrGW8XbgcqurQbnR4MUfy02FzX5vE4DwcYlqwpx2YuO8Yq-PaBbGK3ywcXqqFdcXQpOBZctZ5W6-A9Vl7GT1zFY5-v7IwE9CHSKOSfr7runRK0BUYeAqBoQtQZE3VXNm4dj3yv-JaL9Cx_YuLU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1674685724</pqid></control><display><type>article</type><title>Value of thyroid transcription factor (TTF)-1 for diagnosis and prognosis of patients with locally advanced or metastatic small cell lung cancer</title><source>Springer Open Access</source><source>MEDLINE</source><source>SpringerLink (Online service)</source><source>PubMed Central</source><source>Directory of Open Access Journals</source><source>EZB Electronic Journals Library</source><source>PubMed Central Open Access</source><creator>Misch, Daniel ; Blum, Torsten ; Boch, Christian ; Weiss, Timo ; Crolow, Catharina ; Griff, Sergej ; Mairinger, Thomas ; Bauer, Torsten T ; Kollmeier, Jens</creator><creatorcontrib>Misch, Daniel ; Blum, Torsten ; Boch, Christian ; Weiss, Timo ; Crolow, Catharina ; Griff, Sergej ; Mairinger, Thomas ; Bauer, Torsten T ; Kollmeier, Jens</creatorcontrib><description>The aim of this study was to analyze the frequency of Thyroid Transcription Factor (TTF)-1 expression in small cell lung cancer (SCLC) and its value for the diagnosis of SCLC, the response to first line treatment as well as the prognostic impact on overall survival (OS).
We analyzed a total of 294 patients (m, n = 184; f, n = 110) with SCLC (stage IIIA, n = 32; IIIB, n = 87; IV, n = 175) diagnosed in our institution between January 2005 and December 2008. Patient's characteristics comprising age, gender, histology and first line treatment were included into the analyses. For the follow-up of patients the governmental death registrar was used. The TTF-1 immunostaining was prospectively performed. CT scans of all patients were reviewed and response to treatment was evaluated using the Response Evaluation Criteria In Solid Tumors 1.0 (RECIST) criteria.
A total of 221 of the 294 patients were eligible for analysis. Patients with TTF-1-positive SCLC had a median OS of 374 (95% CI 306-442) days. The OS of patients with TTF1-negative SCLC was 290 (95% CI 191-389) days, which was not significantly shorter (p = 0.254). Also stratification for tumor stage did not reveal significant difference in OS. Analyzing the disease control rate (DCR) in patients with metastatic disease (stage IV), we observed a significantly (p = 0.006) improved response to treatment in the group of patients with TTF-1-expression (DCR 86% vs. 56%). Regarding the overall response rates (ORR) in the entire population, there was no difference observed between both subgroups. (TTF-1-pos. 75.3% vs. TTF-1-neg. 71.4%; p = 0.642).
The diagnostic information of TTF-1 in SCLC seems to be limited. TTF-1 had no prognostic value concerning OS, but may serve as a predictor for response to first line chemotherapy.
The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/5811254651472285.</description><identifier>ISSN: 1746-1596</identifier><identifier>EISSN: 1746-1596</identifier><identifier>DOI: 10.1186/s13000-015-0250-z</identifier><identifier>PMID: 25889870</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Aged ; Analysis ; Biomarkers, Tumor - analysis ; Care and treatment ; Complications and side effects ; Diagnosis ; Diagnostic imaging ; Female ; Humans ; Immunohistochemistry ; Kaplan-Meier Estimate ; Lung cancer, Small cell ; Lung Neoplasms - chemistry ; Lung Neoplasms - mortality ; Lung Neoplasms - pathology ; Lung Neoplasms - therapy ; Male ; Metastasis ; Methods ; Middle Aged ; Neoplasm Staging ; Nuclear Proteins - analysis ; Predictive Value of Tests ; Prognosis ; Retrospective Studies ; Small Cell Lung Carcinoma - chemistry ; Small Cell Lung Carcinoma - mortality ; Small Cell Lung Carcinoma - secondary ; Small Cell Lung Carcinoma - therapy ; Thyroid Nuclear Factor 1 ; Time Factors ; Transcription Factors - analysis ; Treatment Outcome</subject><ispartof>Diagnostic pathology, 2015-04, Vol.10 (1), p.21-21, Article 21</ispartof><rights>COPYRIGHT 2015 BioMed Central Ltd.</rights><rights>Misch et al.; licensee BioMed Central. 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c466t-2af1f24254fe4d711a1122d91d690a935d3cd5a20c8f5e82aff942e1464ad0f93</citedby><cites>FETCH-LOGICAL-c466t-2af1f24254fe4d711a1122d91d690a935d3cd5a20c8f5e82aff942e1464ad0f93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4391673/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4391673/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25889870$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Misch, Daniel</creatorcontrib><creatorcontrib>Blum, Torsten</creatorcontrib><creatorcontrib>Boch, Christian</creatorcontrib><creatorcontrib>Weiss, Timo</creatorcontrib><creatorcontrib>Crolow, Catharina</creatorcontrib><creatorcontrib>Griff, Sergej</creatorcontrib><creatorcontrib>Mairinger, Thomas</creatorcontrib><creatorcontrib>Bauer, Torsten T</creatorcontrib><creatorcontrib>Kollmeier, Jens</creatorcontrib><title>Value of thyroid transcription factor (TTF)-1 for diagnosis and prognosis of patients with locally advanced or metastatic small cell lung cancer</title><title>Diagnostic pathology</title><addtitle>Diagn Pathol</addtitle><description>The aim of this study was to analyze the frequency of Thyroid Transcription Factor (TTF)-1 expression in small cell lung cancer (SCLC) and its value for the diagnosis of SCLC, the response to first line treatment as well as the prognostic impact on overall survival (OS).
We analyzed a total of 294 patients (m, n = 184; f, n = 110) with SCLC (stage IIIA, n = 32; IIIB, n = 87; IV, n = 175) diagnosed in our institution between January 2005 and December 2008. Patient's characteristics comprising age, gender, histology and first line treatment were included into the analyses. For the follow-up of patients the governmental death registrar was used. The TTF-1 immunostaining was prospectively performed. CT scans of all patients were reviewed and response to treatment was evaluated using the Response Evaluation Criteria In Solid Tumors 1.0 (RECIST) criteria.
A total of 221 of the 294 patients were eligible for analysis. Patients with TTF-1-positive SCLC had a median OS of 374 (95% CI 306-442) days. The OS of patients with TTF1-negative SCLC was 290 (95% CI 191-389) days, which was not significantly shorter (p = 0.254). Also stratification for tumor stage did not reveal significant difference in OS. Analyzing the disease control rate (DCR) in patients with metastatic disease (stage IV), we observed a significantly (p = 0.006) improved response to treatment in the group of patients with TTF-1-expression (DCR 86% vs. 56%). Regarding the overall response rates (ORR) in the entire population, there was no difference observed between both subgroups. (TTF-1-pos. 75.3% vs. TTF-1-neg. 71.4%; p = 0.642).
The diagnostic information of TTF-1 in SCLC seems to be limited. TTF-1 had no prognostic value concerning OS, but may serve as a predictor for response to first line chemotherapy.
The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/5811254651472285.</description><subject>Aged</subject><subject>Analysis</subject><subject>Biomarkers, Tumor - analysis</subject><subject>Care and treatment</subject><subject>Complications and side effects</subject><subject>Diagnosis</subject><subject>Diagnostic imaging</subject><subject>Female</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Kaplan-Meier Estimate</subject><subject>Lung cancer, Small cell</subject><subject>Lung Neoplasms - chemistry</subject><subject>Lung Neoplasms - mortality</subject><subject>Lung Neoplasms - pathology</subject><subject>Lung Neoplasms - therapy</subject><subject>Male</subject><subject>Metastasis</subject><subject>Methods</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Nuclear Proteins - analysis</subject><subject>Predictive Value of Tests</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Small Cell Lung Carcinoma - chemistry</subject><subject>Small Cell Lung Carcinoma - mortality</subject><subject>Small Cell Lung Carcinoma - secondary</subject><subject>Small Cell Lung Carcinoma - therapy</subject><subject>Thyroid Nuclear Factor 1</subject><subject>Time Factors</subject><subject>Transcription Factors - analysis</subject><subject>Treatment Outcome</subject><issn>1746-1596</issn><issn>1746-1596</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptks9qFTEUxoMotlYfwI0E3NTF1CSTZGY2QilWhYKbq9twzJ97IzPJmGQqt0_hI5vhXksLEkhOkt_3cQ58CL2m5ILSXr7PtCWENISKhjBBmrsn6JR2XDZUDPLpg_oEvcj5JyFcCEaeoxMm-n7oO3KK_nyHcbE4Olx2-xS9wSVByDr5ufgYsANdYsLnm831u4ZiV2vjYRti9hlDMHhO8XirHjMUb0PJ-LcvOzxGDeO4x2BuIWhrcBVPtkAuFdM4T_UXa1u3cQlbrFcovUTPHIzZvjqeZ-jb9cfN1efm5uunL1eXN43mUpaGgaOOcSa4s9x0lAKljJmBGjkQGFphWm0EMKJ7J2xfcTdwZimXHAxxQ3uGPhx85-XHZI2ubScY1Zz8BGmvInj1-Cf4ndrGW8XbgcqurQbnR4MUfy02FzX5vE4DwcYlqwpx2YuO8Yq-PaBbGK3ywcXqqFdcXQpOBZctZ5W6-A9Vl7GT1zFY5-v7IwE9CHSKOSfr7runRK0BUYeAqBoQtQZE3VXNm4dj3yv-JaL9Cx_YuLU</recordid><startdate>20150402</startdate><enddate>20150402</enddate><creator>Misch, Daniel</creator><creator>Blum, Torsten</creator><creator>Boch, Christian</creator><creator>Weiss, Timo</creator><creator>Crolow, Catharina</creator><creator>Griff, Sergej</creator><creator>Mairinger, Thomas</creator><creator>Bauer, Torsten T</creator><creator>Kollmeier, Jens</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20150402</creationdate><title>Value of thyroid transcription factor (TTF)-1 for diagnosis and prognosis of patients with locally advanced or metastatic small cell lung cancer</title><author>Misch, Daniel ; Blum, Torsten ; Boch, Christian ; Weiss, Timo ; Crolow, Catharina ; Griff, Sergej ; Mairinger, Thomas ; Bauer, Torsten T ; Kollmeier, Jens</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c466t-2af1f24254fe4d711a1122d91d690a935d3cd5a20c8f5e82aff942e1464ad0f93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Aged</topic><topic>Analysis</topic><topic>Biomarkers, Tumor - analysis</topic><topic>Care and treatment</topic><topic>Complications and side effects</topic><topic>Diagnosis</topic><topic>Diagnostic imaging</topic><topic>Female</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Kaplan-Meier Estimate</topic><topic>Lung cancer, Small cell</topic><topic>Lung Neoplasms - chemistry</topic><topic>Lung Neoplasms - mortality</topic><topic>Lung Neoplasms - pathology</topic><topic>Lung Neoplasms - therapy</topic><topic>Male</topic><topic>Metastasis</topic><topic>Methods</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Nuclear Proteins - analysis</topic><topic>Predictive Value of Tests</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Small Cell Lung Carcinoma - chemistry</topic><topic>Small Cell Lung Carcinoma - mortality</topic><topic>Small Cell Lung Carcinoma - secondary</topic><topic>Small Cell Lung Carcinoma - therapy</topic><topic>Thyroid Nuclear Factor 1</topic><topic>Time Factors</topic><topic>Transcription Factors - analysis</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Misch, Daniel</creatorcontrib><creatorcontrib>Blum, Torsten</creatorcontrib><creatorcontrib>Boch, Christian</creatorcontrib><creatorcontrib>Weiss, Timo</creatorcontrib><creatorcontrib>Crolow, Catharina</creatorcontrib><creatorcontrib>Griff, Sergej</creatorcontrib><creatorcontrib>Mairinger, Thomas</creatorcontrib><creatorcontrib>Bauer, Torsten T</creatorcontrib><creatorcontrib>Kollmeier, Jens</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Diagnostic pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Misch, Daniel</au><au>Blum, Torsten</au><au>Boch, Christian</au><au>Weiss, Timo</au><au>Crolow, Catharina</au><au>Griff, Sergej</au><au>Mairinger, Thomas</au><au>Bauer, Torsten T</au><au>Kollmeier, Jens</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Value of thyroid transcription factor (TTF)-1 for diagnosis and prognosis of patients with locally advanced or metastatic small cell lung cancer</atitle><jtitle>Diagnostic pathology</jtitle><addtitle>Diagn Pathol</addtitle><date>2015-04-02</date><risdate>2015</risdate><volume>10</volume><issue>1</issue><spage>21</spage><epage>21</epage><pages>21-21</pages><artnum>21</artnum><issn>1746-1596</issn><eissn>1746-1596</eissn><abstract>The aim of this study was to analyze the frequency of Thyroid Transcription Factor (TTF)-1 expression in small cell lung cancer (SCLC) and its value for the diagnosis of SCLC, the response to first line treatment as well as the prognostic impact on overall survival (OS).
We analyzed a total of 294 patients (m, n = 184; f, n = 110) with SCLC (stage IIIA, n = 32; IIIB, n = 87; IV, n = 175) diagnosed in our institution between January 2005 and December 2008. Patient's characteristics comprising age, gender, histology and first line treatment were included into the analyses. For the follow-up of patients the governmental death registrar was used. The TTF-1 immunostaining was prospectively performed. CT scans of all patients were reviewed and response to treatment was evaluated using the Response Evaluation Criteria In Solid Tumors 1.0 (RECIST) criteria.
A total of 221 of the 294 patients were eligible for analysis. Patients with TTF-1-positive SCLC had a median OS of 374 (95% CI 306-442) days. The OS of patients with TTF1-negative SCLC was 290 (95% CI 191-389) days, which was not significantly shorter (p = 0.254). Also stratification for tumor stage did not reveal significant difference in OS. Analyzing the disease control rate (DCR) in patients with metastatic disease (stage IV), we observed a significantly (p = 0.006) improved response to treatment in the group of patients with TTF-1-expression (DCR 86% vs. 56%). Regarding the overall response rates (ORR) in the entire population, there was no difference observed between both subgroups. (TTF-1-pos. 75.3% vs. TTF-1-neg. 71.4%; p = 0.642).
The diagnostic information of TTF-1 in SCLC seems to be limited. TTF-1 had no prognostic value concerning OS, but may serve as a predictor for response to first line chemotherapy.
The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/5811254651472285.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>25889870</pmid><doi>10.1186/s13000-015-0250-z</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1746-1596 |
| ispartof | Diagnostic pathology, 2015-04, Vol.10 (1), p.21-21, Article 21 |
| issn | 1746-1596 1746-1596 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4391673 |
| source | Springer Open Access; MEDLINE; SpringerLink (Online service); PubMed Central; Directory of Open Access Journals; EZB Electronic Journals Library; PubMed Central Open Access |
| subjects | Aged Analysis Biomarkers, Tumor - analysis Care and treatment Complications and side effects Diagnosis Diagnostic imaging Female Humans Immunohistochemistry Kaplan-Meier Estimate Lung cancer, Small cell Lung Neoplasms - chemistry Lung Neoplasms - mortality Lung Neoplasms - pathology Lung Neoplasms - therapy Male Metastasis Methods Middle Aged Neoplasm Staging Nuclear Proteins - analysis Predictive Value of Tests Prognosis Retrospective Studies Small Cell Lung Carcinoma - chemistry Small Cell Lung Carcinoma - mortality Small Cell Lung Carcinoma - secondary Small Cell Lung Carcinoma - therapy Thyroid Nuclear Factor 1 Time Factors Transcription Factors - analysis Treatment Outcome |
| title | Value of thyroid transcription factor (TTF)-1 for diagnosis and prognosis of patients with locally advanced or metastatic small cell lung cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T10%3A46%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Value%20of%20thyroid%20transcription%20factor%20(TTF)-1%20for%20diagnosis%20and%20prognosis%20of%20patients%20with%20locally%20advanced%20or%20metastatic%20small%20cell%20lung%20cancer&rft.jtitle=Diagnostic%20pathology&rft.au=Misch,%20Daniel&rft.date=2015-04-02&rft.volume=10&rft.issue=1&rft.spage=21&rft.epage=21&rft.pages=21-21&rft.artnum=21&rft.issn=1746-1596&rft.eissn=1746-1596&rft_id=info:doi/10.1186/s13000-015-0250-z&rft_dat=%3Cgale_pubme%3EA541546342%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1674685724&rft_id=info:pmid/25889870&rft_galeid=A541546342&rfr_iscdi=true |